Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases.

Open access
Wucherpfennig, K W, Strominger, J L · 1995 · The Journal of experimental medicine

Abstract

H uman autoimmune diseases have a striking genetic association with particular alleles of major histocompatibility complex (MHC) class I or II genes. The field was established by the seminal discovery of HLA-B27-1inked susceptibility to ankylosing spondylitis, a chronic inflammatory joint disease (1, 2). MHC-associated susceptibility has now been documented for a variety of human autoimmune diseases, including insulin-dependent diabetes meUitus (IDDM), rheumatoid arthritis (RA), pemphigus vulgaris (PV), multiple sclerosis, and myasthenia gravis, just to name a few (3-8). A genome-wide search for diabetes susceptibility genes using microsatellite markers has demonstrated that several genes contribute to the disease process, but that the MHC is the most important susceptibility locus (9). Despite this remarkable progress, several critical questions remain to be answered to establish a causal relationship between the genetics and the immunopathogenesis: (a) Is the role of MHC molecules in autoimmunity based on the presentation of (self) peptides? (b) What is the biochemical nature of these peptides? (c) Are these peptides specific for a particular disease associated MHC molecule and the target organ of the immune attack? (d) What mechanisms induce an autoaggressive T cell response to these self determinants? Recent developments in the field, particularly the structural characterization of MHC-peptide complexes and the identification of allele-specific peptide-binding motifs, have transformed the field (10-13). Based on this knowledge, the structural basis for MHC-linked susceptibility to autoimmune diseases can be reassessed at a level of detail sufficient for solving longstanding questions in the field. Motifs for peptide binding to MHC class I and II molecules were defined by sequence analysis of naturally processed peptides and by mutational analysis of known epitopes. MHC class I-bound peptides were found to be short (generally 8-10 amino acids long) and to possess two dominant MHC anchor residues; MHC class II-bound peptides were found to be longer and more heterogeneous in size (10-17). The size heterogeneity has made it more difficult to define MHC class II-binding motifs based on sequence alignments; the crystal structure of HLA-DK1 has, however, clearly demonstrated that there is a dominant hydrophobic anchor residue close to the NHz terminus of the peptide, and that secondary anchor residues are found at several other peptide positions (13, 15, 18). The peptide-binding site of human HLA-DK molecules is generated by the first domains of the conserved DKot and the polymorphic DK/$ chain. A prominent hydrophobic pocket that is highly conserved between human DR. molecules accommodates the primary anchor residue. Most residues that shape this pocket are from the DR.or chain; however, the size of this pocket is controlled by the Val/Gly dimorphism at position 86 of the DR,8 chain (15, 18). When glycine is present at DKB86, aliphatic or aromatic residues can anchor the peptide; with valine at DRB86, the pocket is smaller so that tyrosine and tryptophan cannot be accommodated (13, 19). In the HLA-DK1 structure, shallower pockets accommodate other peptide side chains, particularly side chains of P4, P6, P7, and P9 (relative to the first anchor Pl). Peptide residues at these positions appear to contribute to the specificity of peptide binding to different D R molecules (13). The fact that both the primary pocket and the hydrogen bonding network along the peptide main chain are highly conserved among different DR` molecules accounts for the fact that a number of high affinity peptides bind to a number of different D R molecules ("promiscuous" binding) (13, 17, 20). How can this observation be reconciled with the hypothesis that the association of different class II alleles is based on selective peptide binding to the disease-associated molecules? The answer to this question, which is the focus of this review, relates to the following facts: (a) Selective and nonselective peptides have been identified (17, 20). (b) Charged residues at two key positions in the class II/3 chain (positions /$71 and/$57) control the charge permitted at peptide position P4 (~71) and P9 (/$57) (for positioning of P4 and P9 in HLA-DR. pockets see reference 13). (c) Nonselective peptides do not carry a charge at these positions (P4 or P9). (d) Peptides with charged residues at P4 and/or P9 can only bind if an opposing charge (or no charge) is present at the respective position in the MHC dass II/$ chain (21). A large body of epidemiological work has documented the association of RA with the following DR. alleles: DR.4 (DRBI*0401, DRBI*0404) and DR1 (DRBI*0101), with the DR,4 alleles conferring a higher risk than DR.I (22). The risk is dramatically increased when the subject is homozygous or heterozygous for DRBI*0401 and/or DRBI*IM04. The importance of DR4 in the development of arthritis is also underscored by the following observations: The vast

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.181.5.1597

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 194

Metadata

Authors
Wucherpfennig, K. W., & Strominger, J. L.
Venue
The Journal of experimental medicine
Published
1995-05-01
Volume
181
Issue
5
Pages
1597-1601
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2059907266
Cited by
194
References
1
FWCI
7.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. https://app.cochat.ai/papers/10.1084/jem.181.5.1597
The paper
Wucherpfennig, K. W., & Strominger, J. L. (1995). Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. The Journal of experimental medicine. https://doi.org/10.1084/jem.181.5.1597

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.